LiLa-Bipolar RCT
Cross-source consensus on LiLa-Bipolar RCT from 1 sources and 6 claims.
1 sources · 6 claims
Comparisons
Other
Other
Other
Other
Other
Highlighted claims
- The trial compares lithium and lamotrigine in newly diagnosed bipolar II disorder patients over 6 months. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)
- The study is a two-arm, single-blinded, parallel-group pragmatic superiority randomised controlled trial. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)
- Participants are randomised equally to lithium or lamotrigine. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)
- Recruitment began on 8 May 2024, and final participant follow-up is expected on 1 December 2027. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)
- The trial aims to include 200 newly diagnosed bipolar II disorder patients. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)
- The trial is conducted at specialised outpatient mood disorder clinics in Copenhagen, Denmark. — Lithium versus lamotrigine in bipolar disorder type II: protocol for a single-blinded, pragmatic, randomised controlled trial (the LiLa-Bipolar RCT)